Sarah Yahia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sarah Yahia has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Ibrahim Mohammed El-Sherbiny
Center for Materials Science, Zewail City of Science and Technology, Cairo 12588, Egypt
5 shared publications Abdelrahman M. Eldaweny
1 shared publicationAbdullah S. Alawam
Department of Biology, College of Science
1 shared publication- Abdullah T. Agamey1 shared publication
Ahmed A. Allam
Department of Biology, College of Science
1 shared publication- Ahmed A. Emam
Medical Experimental Research Center (MERC), Faculty of Medicine, Mansoura University, Mansoura, Egypt
1 shared publication
Latest Publications
- Open Access
- 7 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (17) , 7953
Enhancement of Anti-Neoplastic Effects of MGN-3/Biobran Against Solid Ehrlich Carcinoma-Bearing Mice via Lipidic Nanoparticle Based Targeted Drug Delivery System
MGN-3 (Biobran), a denatured hemicellulose compound derived from rice bran, possesses potent immunomodulatory and antitumor activity; however, its clinical application is constrained by non-specific tissue distribution, rapid systemic elimination, and poor cellular uptake. To overcome these pharmacological limitations, we engineered MGN-3-loaded lipid nanoparticles (MGN-3.LNPs) formulated with bioactive cinnamon and avocado oils to optimize targeted drug delivery against solid carcinoma. Mice bearing subcutaneous Ehrlich Ascites Carcinoma (EAC) solid tumors received free MGN-3, plain lipid nanoparticles (plain LNPs), or MGN-3.LNPs three times weekly from day 8 to day 26 post-inoculation. The administration of MGN-3.LNPs achieved superior tumor volume suppression (95.00%) compared to free MGN-3 (69.00%) and plain LNPs (63.00%) (p < 0.0001). Mechanistically, MGN-3.LNPs effectively inhibited cancer cell proliferation by suppressing Ki-67 expression while promoting expression shifts that strongly suggest the engagement of mitochondrial-mediated apoptotic signaling, including upregulation of tumor protein p53, Caspase-3, Caspase-9, poly(ADP-ribose) polymerase (PARP), and cytosolic cytochrome c (Cyt c), alongside an elevated Bax/Bcl-2 ratio and reduced 8-hydroxy-2′-deoxyguanosine (8-OHdG) levels. Flow cytometric analysis confirmed that MGN-3.LNPs induced marked G0/G1 cell cycle arrest and promoted sub-G1 apoptotic cell accumulation, which was corroborated by Annexin V/propidium iodide (Annexin V/PI) staining and semiquantitative histopathological evaluation. Furthermore, MGN-3.LNPs downregulated the gene expression of proinflammatory cytokines tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) while restoring redox homeostasis in tumor tissues. Overall, lipidic nanoencapsulation significantly enhances the therapeutic efficacy of MGN-3 against solid tumors through superior nanoscale tissue penetration, prolonged retention, and synergistic lipid–drug bioactivity.
- 7 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (17) , 7953
Open AccessEnhancement of Anti-Neoplastic Effects of MGN-3/Biobran Against Solid Ehrlich Carcinoma-Bearing Mice via Lipidic Nanoparticle Based Targeted Drug Delivery System
MGN-3 (Biobran), a denatured hemicellulose compound derived from rice bran, possesses potent immunomodulatory and antitumor activity; however, its clinical application is constrained by non-specific tissue distribution, rapid systemic elimination, and poor cellular uptake. To overcome these pharmacological limitations, we engineered MGN-3-loaded lipid nanoparticles (MGN-3.LNPs) formulated with bioactive cinnamon and avocado oils to optimize targeted drug delivery against solid carcinoma. Mice bearing subcutaneous Ehrlich Ascites Carcinoma (EAC) solid tumors received free MGN-3, plain lipid nanoparticles (plain LNPs), or MGN-3.LNPs three times weekly from day 8 to day 26 post-inoculation. The administration of MGN-3.LNPs achieved superior tumor volume suppression (95.00%) compared to free MGN-3 (69.00%) and plain LNPs (63.00%) (p < 0.0001). Mechanistically, MGN-3.LNPs effectively inhibited cancer cell proliferation by suppressing Ki-67 expression while promoting expression shifts that strongly suggest the engagement of mitochondrial-mediated apoptotic signaling, including upregulation of tumor protein p53, Caspase-3, Caspase-9, poly(ADP-ribose) polymerase (PARP), and cytosolic cytochrome c (Cyt c), alongside an elevated Bax/Bcl-2 ratio and reduced 8-hydroxy-2′-deoxyguanosine (8-OHdG) levels. Flow cytometric analysis confirmed that MGN-3.LNPs induced marked G0/G1 cell cycle arrest and promoted sub-G1 apoptotic cell accumulation, which was corroborated by Annexin V/propidium iodide (Annexin V/PI) staining and semiquantitative histopathological evaluation. Furthermore, MGN-3.LNPs downregulated the gene expression of proinflammatory cytokines tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) while restoring redox homeostasis in tumor tissues. Overall, lipidic nanoencapsulation significantly enhances the therapeutic efficacy of MGN-3 against solid tumors through superior nanoscale tissue penetration, prolonged retention, and synergistic lipid–drug bioactivity.
- 1 July 2026
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 125
A synergistic dual-action nanotherapeutic platform for osteosarcoma treatment
- 1 July 2026
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 125
A synergistic dual-action nanotherapeutic platform for osteosarcoma treatment
- Open Access
- 26 February 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (3) , 116
Fortified Long-acting Ocular Gel Laden with Nanoformulated Dexamethasone for Dry Eye Therapy
Dry eye disease (DED) is a rampant and multifactorial ocular disorder. Conventional ocular drug delivery faces significant challenges due to the complex oc
- 26 February 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (3) , 116
Open AccessFortified Long-acting Ocular Gel Laden with Nanoformulated Dexamethasone for Dry Eye Therapy
Dry eye disease (DED) is a rampant and multifactorial ocular disorder. Conventional ocular drug delivery faces significant challenges due to the complex oc
- Open Access
- 31 July 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (31) , 34106-34122
Emerging Electrochemical Approaches for the Early Detection of Programmed Cell Death
Programmed cell death (apoptosis) safeguards tissue homeostasis, and its dysregulation is a hallmark of cancer, neurodegeneration, and immune disorders. Detecting the earliest biochemical signatures of apoptosis therefore offers a route to sharper diagnosis, real-time therapy monitoring, and data-driven drug discovery. Electrochemical biosensors are uniquely suited to this task because they translate molecular recognition events into electrical signals that are rapid, miniaturizable, and inherently compatible with point-of-care formats. Yet their clinical translation is still limited by three persistent hurdles: (i) selective recognition in protein-rich or highly variable matrices, (ii) long-term signal stability under continuous operation, and (iii) a lack of unified analytical performance standards that hampers cross-platform benchmarking. This critical review charts the most recent material, biochemical, and microelectronic innovations that are beginning to erode these barriers, and identifies emerging strategiesfrom nanostructured electrode interfaces to signal processing that could propel electrochemical apoptosis sensing from proof-of-concept prototypes to reliable bedside tools. By aligning unresolved challenges with promising technological solutions, we aim to guide interdisciplinary efforts toward next-generation diagnostics capable of real-time apoptosis surveillance in complex biological settings.
- 31 July 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (31) , 34106-34122
Open AccessEmerging Electrochemical Approaches for the Early Detection of Programmed Cell Death
Programmed cell death (apoptosis) safeguards tissue homeostasis, and its dysregulation is a hallmark of cancer, neurodegeneration, and immune disorders. Detecting the earliest biochemical signatures of apoptosis therefore offers a route to sharper diagnosis, real-time therapy monitoring, and data-driven drug discovery. Electrochemical biosensors are uniquely suited to this task because they translate molecular recognition events into electrical signals that are rapid, miniaturizable, and inherently compatible with point-of-care formats. Yet their clinical translation is still limited by three persistent hurdles: (i) selective recognition in protein-rich or highly variable matrices, (ii) long-term signal stability under continuous operation, and (iii) a lack of unified analytical performance standards that hampers cross-platform benchmarking. This critical review charts the most recent material, biochemical, and microelectronic innovations that are beginning to erode these barriers, and identifies emerging strategiesfrom nanostructured electrode interfaces to signal processing that could propel electrochemical apoptosis sensing from proof-of-concept prototypes to reliable bedside tools. By aligning unresolved challenges with promising technological solutions, we aim to guide interdisciplinary efforts toward next-generation diagnostics capable of real-time apoptosis surveillance in complex biological settings.
- 29 July 2024
- Published by Springer Nature in Regenerative Engineering and Translational Medicine
- Vol. 11 (1) , 190-208
Photobiostimulation Enhances the Osteogenic Differentiation of Gingival-Derived Stem Cells Seeded on Nanocomposite Scaffolds
- 29 July 2024
- Published by Springer Nature in Regenerative Engineering and Translational Medicine
- Vol. 11 (1) , 190-208
Photobiostimulation Enhances the Osteogenic Differentiation of Gingival-Derived Stem Cells Seeded on Nanocomposite Scaffolds